Navepegritide (Yuviwel) — Coverage Criteria for Achondroplasia
Customize your policy alerts
Sign up for QualChoice Policy CP.PHAR.746 alerts
Get alerted when Policy CP.PHAR.746 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity and prior authorization requirements for navepegritide (Yuviwel) for pediatric achondroplasia across applicable QualChoice lines of business (Commercial, ICHRA/HIM, Medicaid). Affects providers requesting coverage for initiation and continuation of therapy.
Criteria updated per prescribing information to include weight-based dosing and quantity limits.
Added requirement that Yuviwel is not prescribed concurrently with Voxzogo and any human growth hormone products for continued therapy.
ICHRA (health insurance marketplace/ICHRA) line of business was added.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.